Systemic Biologic Management of Atopic Dermatitis

• DOI: 10.1007/978-3-031-54513-9_13
• Publication Date: 2024-05-09T18:06:38Z
• Authors: Diem-Phuong D. Dao; R. Hal Flowers
• Keywords: Biological Therapy; Treatment Outcome; Humans; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Dermatitis, Atopic

Dupilumab and tralokinumab are currently the only FDA-approved biologic therapies for the treatment of moderate-to-severe atopic dermatitis. Tralokinumab is approved for patients greater than 18 years old, and dupilumab is approved for patients as young as 6 months old. Both medications are effective in clinical trials at improving atopic dermatitis. With a good safety profile and low-risk adverse events, dupilumab and tralokinumab are generally excellent treatment options for patients with severe or refractory atopic dermatitis.